Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New Imaging Approach Could Help Predict Dangerous Gut Infection

By LabMedica International staff writers
Posted on 10 Mar 2026

Clostridioides difficile infections affect roughly half a million people in the United States each year and are a leading cause of infectious diarrhea in healthcare settings. More...

The bacterium can trigger severe intestinal inflammation, recurring illness, and life-threatening complications, particularly in older adults. Despite available treatments, controlling C. diff infections remains difficult because the bacterium can survive harsh conditions and frequently reappears after treatment. Researchers are now investigating the bacterium at multiple biological levels to uncover vulnerabilities that could lead to improved prevention and treatment strategies.

Scientists at Tufts University School of Medicine (Boston, MA, USA) are studying how C. diff behaves inside the body and how its spores reactivate to cause infection. C. diff infections typically occur after antibiotics disrupt the natural gut microbiome, allowing the bacterium to colonize the colon and release toxins that damage intestinal tissues. To better understand how the infection progresses, researchers developed an imaging technique that tracks individual bacterial cells inside infected tissue. Using fluorescent markers that highlight gene activity, the team observed where C. diff cells were located and which cells activated toxin production during infection.

The analysis revealed that C. diff bacteria can spread throughout the gut and reside closer to the intestinal lining than previously thought. Surprisingly, only a small subset of bacterial cells produced toxins at any given time, suggesting that disease severity may be driven by specific subpopulations rather than overall bacterial numbers. The study, published in Nature Communications and PLOS Biology, also identified unusual filament-like shapes formed by highly toxin-producing strains during early infection stages, indicating that these cells may respond differently to environmental stress.

Researchers also examined how C. diff spores transition from a dormant state into active bacteria. Unlike most spore-forming bacteria, C. diff responds to bile acids and other digestive signals to trigger germination. The team identified two proteins—CspC and CspA—that work together as a signaling hub controlling this activation process. Structural analysis showed that this protein complex regulates how sensitive spores are to environmental signals that trigger growth.

These findings provide a clearer understanding of how C. diff infections develop, spread, and reactivate. By identifying the molecular mechanisms that control toxin production and spore germination, researchers hope to develop targeted treatments that block infection without disrupting beneficial gut bacteria. Future research will continue exploring unique biological processes in C. diff that could reveal new drug targets and help clinicians better predict which patients are at risk of severe or recurrent infection.

“The hope is the aspects that make C. diff unique—how it spreads, reproduces, and damages tissue—will allow researchers to design ways to target it much more specifically, while keeping the rest of the gut microbiome healthy and intact,” said associate professor Aimee Shen.

Related Links:
Tufts University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.